Table 4. Out-of-Pocket Spending per Beneficiary for Top-Selling Ultra-Expensive Drugs, 2019a.
| Product (Part D spending, $ millions) | Measurement | Overall, $ | |
|---|---|---|---|
| Part D | Commercial insurance | ||
| Lenalidomide (4674) | Mean | 5401 (n = 6491)b | 1248 (n = 1716) |
| Median (IQR) | 4452 (1152-9171) | 300 (70-1083) | |
| Ibrutinib (2440) | Mean | 4792 (n = 3917)b | 1548 (n = 795) |
| Median (IQR) | 4308 (1017-8642) | 540 (108-1734) | |
| Palbociclib (1826) | Mean | 4076 (n = 2877)b | 1998 (n = 1333) |
| Median (IQR) | 3643 (564-6791) | 300 (24-1572) | |
| Enzalutamide (1421) | Mean | 2980 (n = 3067)b | 1181 (n = 390) |
| Median (IQR) | 2427 (268-4806) | 250 (6.3-1000) | |
| Pomalidomide (1192) | Mean | 4816 (n = 1689)b | 947 (n = 402) |
| Median (IQR) | 3639 (896-8096) | 150 (0-672) | |
| Dimethyl fumarate (1131) | Mean | 3997 (n = 1191)b | 2144 (n = 2619) |
| Median (IQR) | 5025 (1168-6048) | 600 (240-2057) | |
| Ruxolitinib (1125) | Mean | 5692 (n = 1623)b | 1991 (n = 404) |
| Median (IQR) | 5726 (2211-9551) | 320 (0-1006) | |
| Ustekinumab (796) | Mean | 1596 (n = 817) | 1760 (n = 4546) |
| Median (IQR) | 345 (120-2509) | 390 (150-1473) | |
| Nintedanib (790) | Mean | 3666 (n = 1838)b | 1444 (n = 211) |
| Median (IQR) | 3285 (875-6101) | 300 (80-1173) | |
| Ledipasvir-sofosbuvir (745) | Mean | 4603 (n = 567)b | 2470 (n = 595) |
| Median (IQR) | 5111 (3488-6593) | 240 (84-1604) | |
a
Top-selling is defined in terms of total spending reported in Medicare Part D Spending by Drug data.
b
P < .001.